Literature DB >> 11135158

Bronchioloalveolar carcinoma of the lung: recurrences and survival in patients with stage I disease.

O S Breathnach1, D J Kwiatkowski, D M Finkelstein, J Godleski, D J Sugarbaker, B E Johnson, S Mentzer.   

Abstract

OBJECTIVES: The aim of our study was to retrospectively compare the patient characteristics, the frequency and pattern of recurrent disease, and survival in patients with stage I bronchioloalveolar carcinoma and adenocarcinoma of the lung.
METHODS: Patients with stage I bronchioloalveolar carcinoma or adenocarcinoma other than bronchioloalveolar carcinoma resected between 1984 and 1992 with adequate clinical follow-up were studied. The clinical characteristics of the patients, extent of initial surgical resection, sites of recurrent disease, and overall survival were examined and compared between the 2 groups. The median follow-up for patients with bronchioloalveolar carcinoma and adenocarcinoma was 6.2 years and 5.9 years, respectively.
RESULTS: A total of 138 patients were identified. Thirty-three patients had bronchioloalveolar carcinoma and 105 patients had adenocarcinoma. Eleven (33%) of the patients with bronchioloalveolar carcinoma had never smoked cigarettes versus 9 (9%) of the patients with adenocarcinoma (P =.0036). There were no significant differences between patients with bronchioloalveolar carcinoma and adenocarcinoma in sex distribution and overall recurrence rate. Of the 12 patients with recurrent bronchioloalveolar carcinoma, 1 patient (8%) had extrathoracic disease develop at the site of first recurrence compared with 49% of patients with recurrent adenocarcinoma (P <.001). The 5-year survival in patients with bronchioloalveolar carcinoma and in those with adenocarcinoma was 83% and 63%, respectively (P =.04).
CONCLUSIONS: Stage I bronchioloalveolar carcinoma is more likely to occur in nonsmokers. Survival is longer in patients with bronchioloalveolar carcinoma. Further research is warranted to define the etiology, clinical course, and molecular abnormalities in patients with bronchioloalveolar carcinoma to generate more effective therapeutic approaches.

Entities:  

Mesh:

Year:  2001        PMID: 11135158     DOI: 10.1067/mtc.2001.110190

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  14 in total

1.  The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients.

Authors:  Morgan L Cox; Chi-Fu Jeffrey Yang; Paul J Speicher; Kevin L Anderson; Zachary W Fitch; Lin Gu; Robert Patrick Davis; Xiaofei Wang; Thomas A D'Amico; Matthew G Hartwig; David H Harpole; Mark F Berry
Journal:  J Thorac Oncol       Date:  2017-01-08       Impact factor: 15.609

2.  Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504).

Authors:  Suresh S Ramalingam; Ju-Whei Lee; Chandra P Belani; Seena C Aisner; Jill Kolesar; Craig Howe; Mario R Velasco; Joan H Schiller
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

3.  Case report: Positron emission tomography fails to detect pulmonary adenocarcinoma recurrence after radiofrequency ablation.

Authors:  Cara Odenthal; Karin Steinke
Journal:  J Radiol Case Rep       Date:  2013-11-01

Review 4.  Reclassification of early stage pulmonary adenocarcinoma and its consequences.

Authors:  Annikka Weissferdt; Cesar A Moran
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

5.  Tumour standardized uptake value on positron emission tomography is a novel predictor of adenocarcinoma in situ for c-Stage IA lung cancer patients with a part-solid nodule on thin-section computed tomography scan.

Authors:  Aritoshi Hattori; Kenji Suzuki; Takeshi Matsunaga; Mariko Fukui; Yukio Tsushima; Kazuya Takamochi; Shiaki Oh
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-12-18

6.  Breast cancer anti-estrogen resistance protein 1 (BCAR1/p130cas) in pulmonary disease tissue and serum.

Authors:  Bo Deng; Wei Huang; Qun-You Tan; Xiao-Qing Fan; Yao-Guang Jiang; Ling Liu; Ya-Yi Zhong; Yong-Gang Liang; Ru-Wen Wang
Journal:  Mol Diagn Ther       Date:  2011-02-01       Impact factor: 4.074

Review 7.  Mind-mapping for lung cancer: towards a personalized therapeutics approach.

Authors:  N Mollberg; M Surati; C Demchuk; R Fathi; A K Salama; A N Husain; T Hensing; R Salgia
Journal:  Adv Ther       Date:  2011-02-09       Impact factor: 3.845

8.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.

Authors:  A Bhattacharjee; W G Richards; J Staunton; C Li; S Monti; P Vasa; C Ladd; J Beheshti; R Bueno; M Gillette; M Loda; G Weber; E J Mark; E S Lander; W Wong; B E Johnson; T R Golub; D J Sugarbaker; M Meyerson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-13       Impact factor: 11.205

9.  Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features.

Authors:  Sarit Aviel-Ronen; Bradley P Coe; Suzanne K Lau; Gilda da Cunha Santos; Chang-Qi Zhu; Dan Strumpf; Igor Jurisica; Wan L Lam; Ming-Sound Tsao
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-15       Impact factor: 11.205

10.  Yes associated protein is a poor prognostic factor in well-differentiated lung adenocarcinoma.

Authors:  Mi Hyun Kim; Young Keum Kim; Dong Hoon Shin; Hyun Jeong Lee; Nari Shin; Arong Kim; Jung Hee Lee; Kyung Un Choi; Jee Yeon Kim; Chang Hun Lee; Mee Young Sol
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.